Products
Vaccines are one of the best ways to prevent the world’s most common and dangerous infectious diseases.
Smart Vaccines – a new generation of vaccines
Intercell has specialized in the development of “smart vaccines”, which include only the essential ingredients and which stimulates both sides of the immune system: T-cells and B-cells.
Intercell’s first product on the market is a Japanese Encephalitis vaccine. The product is approved in the U.S. (FDA), Europe (European Commission), Canada (Health Canada) and Australia (TGA).
Our vaccine patch against Travelers’ Diarrhea is tested in Phase III trials. If approved, it will be the first vaccine delivered with a patch and to prevent Travelers’ Diarrhea.
The vaccine candidate in Phase II/III (sequential design) clinical trails targeting Staphylococcus aureus, is based on a conserved protein antigen discovered by Intercell and licensed to Merck & Co., Inc. on an exclusive worldwide basis.
The vaccine aiming to prevent Pseudomonas, currently in Phase II clinical trial, is being developed in-house and has shown excellent results in completed clinical trials.
Our therapeutic vaccine against Hepatitis C has shown statistically significant viral load reduction and an excellent safety profile in completed Phase II trials.
We are developing a Pandemic Influenza vaccine (Phase II) using our groundbreaking vaccine-patch technology. The program is fully funded by the United States Department of Health and Human Services.
The vaccine against Seasonal Influenza, currently in Phase I clinical trials, combines our adjuvant IC31® with a seasonal, trivalent Influenza vaccine from Novartis.
The vaccine against Tuberculosis (in Phase I/II clinical trials) uses our adjuvant IC31® with antigens from Statens Serum Institut and sanofi-aventis.
We are developing a novel protein-based vaccine targeting infections caused by the majority of pneumococcal strains. A Phase I clinical trial was initiated in April 2009. The program is supported by PATH.
In 2006, Intercell and Merck & Co., Inc., entered into a partnership for the development of a vaccine against Group A Streptococcus infections.
A vaccine candidate targeting an undisclosed bacterial pathogen is currently being developed by our partner sanofi-aventis.
We are developing a vaccine against Lyme Borreliosis. The vaccine, targeting all three species causing disease, is currently in pre-clinical development.
In addition to vaccines, we are developing antibodies against infection diseases including Streptococcus aureus, Pneumococcus, Group A Streptococcus and Group B Streptococcus.